PRLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows limited positive momentum, with no significant trading signals or catalysts to justify immediate investment. While analysts have raised the price target and see potential upside, the company's financial performance and technical indicators suggest caution.
The stock's MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 65.711, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), there is no strong confirmation of a breakout. The stock is trading near resistance levels (R1: 3.576), which could limit further upside in the short term.
Analysts have raised the price target to $6 from $3, citing potential best-in-class selectivity and disease-modifying potential for the company's preclinical JAK2V617F data. Gross margin remains strong at 100%.
The stock has a 60% chance of declining by -1.45% in the next day, -4.04% in the next week, and -10.98% in the next month. Financial performance shows a significant drop in net income (-42.72% YoY) and EPS (-44.74% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased by 41.00% YoY to $5.64M, but net income dropped significantly to -$16.46M (-42.72% YoY), and EPS fell to -0.21 (-44.74% YoY). Gross margin remained stable at 100%.
Citizens raised the price target to $6 from $3 and maintained an Outperform rating, highlighting the company's unique investment opportunity and meaningful upside potential.
